Literature DB >> 12471096

Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells.

Giuseppe Penna1, Marisa Vulcano, Andrea Roncari, Fabio Facchetti, Silvano Sozzani, Luciano Adorini.   

Abstract

To examine the different roles of myeloid dendritic cells (M-DCs) and plasmacytoid dendritic cells (P-DCs) in the induction and regulation of immune response, we have studied chemokine secretion by freshly isolated DC subsets in response to bacterial, viral, and T cell-derived stimuli. M-DCs selectively produced very high levels of the homeostatic chemokines CC chemokine ligand (CCL)17 and CCL22, while P-DCs produced very little if any. In contrast, the proinflammatory chemokine CCL3 was secreted mostly by P-DCs, whereas CCL4 and CXC chemokine ligand 8 were produced by both subsets. The selective production of CCL17 and CCL22 by M-DCs but not P-DCs was confirmed in vivo by immunohistology on human reactive lymph node sections. The high production of CCR4 ligands by M-DCs suggests their capacity to selectively recruit at sites of inflammation T cells with regulatory properties or with a Th2 phenotype, whereas P-DCs, by preferentially secreting CCR1/CCR5 ligands, would mostly recruit effector T cells and, in particular, Th1-type cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12471096     DOI: 10.4049/jimmunol.169.12.6673

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

Review 1.  The plasmacytoid monocyte/interferon producing cells.

Authors:  Fabio Facchetti; William Vermi; David Mason; Marco Colonna
Journal:  Virchows Arch       Date:  2003-10-28       Impact factor: 4.064

Review 2.  [Significance of dendritic cells for the immunotherapy of tumors].

Authors:  J B Weise; S Maune; D Kabelitz; A Heiser
Journal:  HNO       Date:  2005-02       Impact factor: 1.284

3.  Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors.

Authors:  Bernard Piqueras; John Connolly; Heidi Freitas; Anna Karolina Palucka; Jacques Banchereau
Journal:  Blood       Date:  2005-11-29       Impact factor: 22.113

Review 4.  Plasmacytoid dendritic cells: in search of their niche in immune responses.

Authors:  Winfried Barchet; Amanda Blasius; Marina Cella; Marco Colonna
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  The role of type I interferon production by dendritic cells in host defense.

Authors:  P Fitzgerald-Bocarsly; D Feng
Journal:  Biochimie       Date:  2007-05-08       Impact factor: 4.079

6.  Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells.

Authors:  Jeong Won Shin; Ping Jin; Yong Fan; Stefanie Slezak; Virginia David-Ocampo; Hanh M Khuu; Elizabeth J Read; Ena Wang; Francesco M Marincola; David F Stroncek
Journal:  Transfusion       Date:  2008-02-12       Impact factor: 3.157

Review 7.  Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history.

Authors:  Patricia Fitzgerald-Bocarsly; Jihong Dai; Sukhwinder Singh
Journal:  Cytokine Growth Factor Rev       Date:  2008-01-11       Impact factor: 7.638

8.  An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells.

Authors:  Robbert van der Voort; Viviènne Verweij; Theo M de Witte; Edwin Lasonder; Gosse J Adema; Harry Dolstra
Journal:  J Leukoc Biol       Date:  2010-02-24       Impact factor: 4.962

9.  Characterization of virus-responsive plasmacytoid dendritic cells in the rhesus macaque.

Authors:  Eugene Chung; Sheela B Amrute; Kristina Abel; Gunjan Gupta; Yichuan Wang; Christopher J Miller; Patricia Fitzgerald-Bocarsly
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

10.  Phenotypic and functional abnormalities of bone marrow-derived dendritic cells in systemic lupus erythematosus.

Authors:  Ying J Nie; Mo Y Mok; Godfrey C F Chan; Albert W Chan; O U Jin; Sushma Kavikondala; Albert K W Lie; Chak S Lau
Journal:  Arthritis Res Ther       Date:  2010-05-18       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.